NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
L-Dopa, the main Parkinson's disease treatment, unexpectedly alters the postsynaptic architecture of cultured mouse neurons through its incorporation into α-tubulin via tubulin tyrosine ligase (TTL). This leads to the formation of L-Dopa-modified microtubules, with impaired dynamics and reduced entry into dendritic spines, increasing their vulnerability to pruning. As a result, dendritic spine density-particularly mature spines-and the number of excitatory synapses are significantly reduced. L-Dopa-mediated synaptic defects are absent in neurons lacking the ability to incorporate it into α-tubulin-TTL or SVBP knockout neurons-confirming a microtubule-dependent mechanism. In vitro, L-Dopa-modified tubulin interfered with VASH1-SVBP activity, the major brain's tubulin carboxypeptidase, potentially prolonging L-Dopa-microtubule persistence and turning this therapeutic agent into a driver of long-lasting neuronal changes. These findings reveal a novel mechanism of L-Dopa-induced synaptotoxicity-mediated by the disruption of microtubule dynamics and the tubulin tyrosination/detyrosination cycle-with possible implications for the long-term adverse effects of L-Dopa therapy.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.